These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31990600)

  • 1. Downregulated CMTM2 Poses Potential Clinical Significance in Hepatocellular Carcinoma.
    Guo X; Zhang S; Tan S; Bei C; Zhang H; Zhu X; Qiu X
    DNA Cell Biol; 2020 Apr; 39(4):683-689. PubMed ID: 31990600
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Li D; Huang S; Luo C; Xu Y; Fu S; Liu K; Wu J
    Curr Oncol; 2023 Feb; 30(3):2653-2672. PubMed ID: 36975415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC.
    Liu Y; Liu L; Zhou Y; Zhou P; Yan Q; Chen X; Ding S; Zhu F
    Clin Cancer Res; 2019 Jul; 25(13):4141-4154. PubMed ID: 30918019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Serum CMTM2 as a Potential Biomarker for HBV-Related Disorders.
    Chen S; Hu Q; Chen H; Zhang FF; Duan L; Wang B; Li DD; Zhang J; Chen WX
    Dis Markers; 2020; 2020():2032056. PubMed ID: 33101541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
    Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
    BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
    Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
    BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma.
    Zhu X; Qi G; Li C; Bei C; Tan C; Zhang Y; Shi W; Zeng W; Kong J; Fu Y; Tan S
    DNA Cell Biol; 2019 Feb; 38(2):193-197. PubMed ID: 30562063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
    Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
    World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
    Liu T; Chen J; Xiao S; Lei X
    Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlation of NLRC3 expression with the progression and prognosis of hepatocellular carcinoma.
    Ma YY; Zhang GH; Li J; Wang SB; Hu ZM; Zhang CW; Li E
    Hum Pathol; 2018 Dec; 82():273-281. PubMed ID: 30081150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDHR5 inhibits proliferation of hepatocellular carcinoma and predicts clinical prognosis.
    Ding X; Tian X; Liu W; Li Z
    Ir J Med Sci; 2020 May; 189(2):439-447. PubMed ID: 31482521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of TRMT6 in Hepatocellular Carcinoma: A Bioinformatics-Based Study.
    Wang Y; Huang Q; Deng T; Li BH; Ren XQ
    Med Sci Monit; 2019 May; 25():3894-3901. PubMed ID: 31128068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.
    Zhang S; Tian R; Bei C; Zhang H; Kong J; Zheng C; Song X; Li D; Tan H; Zhu X; Tan S
    Onco Targets Ther; 2020; 13():5731-5741. PubMed ID: 32606785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
    Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
    J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression Pattern and Clinical Significance of Gab2 Protein in Hepatocellular Carcinoma.
    Hu X; He B; Zhou L; Xie H; Zheng S
    Clin Lab; 2016; 62(6):1087-92. PubMed ID: 27544933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined aberrant expression of N-Myc downstream-regulated gene 2 and CD24 is associated with disease-free survival and overall survival in patients with hepatocellular carcinoma.
    Li B; Shao Q; Ji D; Li F; Guo X; Chen G
    Diagn Pathol; 2014 Oct; 9():209. PubMed ID: 25338637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased levels of miR-34a and miR-217 act as predictor biomarkers of aggressive progression and poor prognosis in hepatocellular carcinoma.
    Tian YW; Shen Q; Jiang QF; Wang YX; Li K; Xue HZ
    Minerva Med; 2017 Apr; 108(2):108-113. PubMed ID: 27879964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulated expression of DIXDC1 in hepatocellular carcinoma and its correlation with prognosis.
    Zhou S; Shen J; Lin S; Liu X; Xu M; Shi L; Wang X; Cai X
    Tumour Biol; 2016 Oct; 37(10):13607-13616. PubMed ID: 27468723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.